Interaction Between Quetiapine and Flecainide: Cardiac Risks and Management

Mechanism of Interaction and Clinical Significance

Flecainide, a class IC antiarrhythmic, blocks sodium channels, affecting cardiac conduction primarily by prolonging the QRS interval, and quetiapine can also affect cardiac repolarization, increasing arrhythmia risk when combined, according to the European Heart Journal 1, 2
The European Heart Journal notes that flecainide has been associated with increased mortality in patients with structural heart disease, and this risk may be compounded by concurrent quetiapine use 1, 3

The European Heart Journal recommends obtaining baseline ECG prior to initiating either medication and monitoring QRS duration regularly, with an increase >25% from baseline indicating potential proarrhythmia risk requiring dose reduction or discontinuation, although this is also noted by Praxis Medical Insights 2
Patients at highest risk for adverse outcomes include those with structural heart disease or coronary artery disease, as noted by the European Heart Journal 1, 4
For atrial fibrillation, amiodarone may be safer in patients with structural heart disease, according to the European Heart Journal 4, 5
If concurrent use is unavoidable, the European Heart Journal and Praxis Medical Insights suggest using the lowest effective doses of both medications, implementing a strict ECG monitoring schedule, and considering cardiology consultation for specialized management 2, 3